FIELD: medicine.
SUBSTANCE: invention relates to variants of a trispecific binding molecule comprising a variable VHH domain, specifically binding human IL-17A and IL-17F, and a domain containing variable heavy and light chain domains and specifically binding human TNF-alpha. Also proposed: nucleic acid encoding said molecule, expression vector, host cell and method for producing a trispecific molecule according to the invention. In addition, a pharmaceutical composition and methods for treating diseases mediated by human IL-17A, IL-17F or TNF-alpha, such as rheumatoid arthritis, psoriasis or psoriatic arthritis, are presented.
EFFECT: this invention may find further application in the prevention and treatment of various autoimmune and inflammatory disorders.
27 cl, 29 dwg, 11 tbl, 30 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL IL-17-BINDING COMPOUNDS AND THEIR MEDICINAL APPLICATION | 2010 |
|
RU2550272C2 |
| HIGH AFFINITY AND AGGREGATIONALLY STABLE ANTIBODIES BASED ON VL VARIABLE DOMAINS AND VHH DERIVATIVE | 2014 |
|
RU2609627C2 |
| ANTI-IL-17 ANTIBODIES, METHODS OF THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2577228C2 |
| ANTI-IL-17F ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2605318C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
| IL-17A LINKING AGENT AND METHODS FOR USE THEREOF | 2014 |
|
RU2682046C1 |
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
| METHODS FOR TREATMENT USING ANTI-IL-17A ANTIBODIES | 2016 |
|
RU2754683C2 |
| MULTISPECIFIC ANTIBODY WITH BINDING SPECIFICITY OF HUMAN IL-13 AND IL-17 | 2020 |
|
RU2827946C1 |
